Management of Marfan Syndrome - An Insight

Introduction

Marfan syndrome disrupts the connective tissues that hold the body together. This issue affects multiple body sections, so one must see various healthcare doctors specializing in these areas. Treatments extend the lives of persons suffering from Marfan syndrome. Marfan syndrome is characterized by abnormal connective tissue. As a result, various biological systems are impacted, including the heart and blood vessels, bones, tendons, cartilage, eyes, skin, and lungs.

What Causes Marfan's Syndrome?

• Marfan syndrome is caused by a genetic abnormality that affects the structure of fibrillin and elastic fibers, which are important connective tissue components. This gene is known as fibrillin-1 or FBN1.

• Most cases of Marfan syndrome are hereditary. The pattern is known as "autosomal dominant," which means it affects both men and women and can be inherited from a single parent with Marfan syndrome. People with Marfan syndrome have a 50 percent probability of passing the disorder down to their children.

• A new gene abnormality arises in 25 percent of instances for unexplained reasons. Marfan syndrome is also known as a "variable expression" genetic disorder since not everyone with the condition has the same symptoms, and some people experience them more severely than others.

• Marfan syndrome is present from birth. However, it may not be diagnosed until a teenager or early adult.

What Are the Symptoms of Marfan Syndrome?

Sometimes, Marfan syndrome is so mild that few, if any, symptoms appear right away. Most symptoms appear as changes in connective tissue occur with age. As Marfan syndrome affects connective tissue, it can affect the entire body, including the skeletal system, heart and blood vessels, eyes, skin, and organs. Marfan syndrome characteristics may include:

• Tall and slim build.

• Extremely lengthy limbs, legs, and fingers.

• A breastbone protrudes outward or dips inward.

• A high, arched palate with crowded teeth.

• Heart murmurs.

• Extreme nearsightedness.

• An excessively bent spine.

• Flat feet.

What Is the Diagnosis of Marfan Syndrome?

There is no single test that can diagnose Marfan syndrome. Instead, the doctor may classify the disease as:

• Inquire about family and medical history, particularly whether any family members have the disorder or had an early, unexplained heart condition.

• Perform a physical exam, which may include:

  • Measuring how lengthy limbs and legs are about the trunk.

  • Examine eyes, skin, and musculoskeletal system.

  • Listen to the heart and lungs.

• Order diagnostic tests to assess the heart, lungs, and eyes, which may include:

  • A computed tomography scan or chest magnetic resonance imaging examines the heart, lungs, and surrounding tissues.

  • Echocardiography evaluates the heart's anatomy, valves, and blood arteries.

  • Order tests to rule out any other illnesses that could be affecting symptoms.

How Is Marfan Syndrome Managed?

Generally, one should anticipate having some daily considerations, such as prescriptions and physical activity constraints. Then, there are routine doctor appointments, which might be yearly or more often, and additional evaluations to ensure that Marfan's traits do not deteriorate. Doctors sometimes prescribe surgery to avoid or correct an issue as features evolve. In some circumstances, one will have time to prepare for an operation; in others, immediate surgery may be required.

Medical Care

The general guidelines for all adults with Marfan syndrome (MFS) are as follows:

• Physical activity restrictions include avoiding contact sports, isometric exercise, and activities that can cause joint injury or pain.

• Avoid drugs that stimulate the cardiovascular system, such as decongestants and coffee.

• Annual ophthalmic examination - refractive error correction with Laser-Assisted In Situ Keratomileusis is not suggested.

• Subacute endocarditis prevention for dental procedures in the presence of mitral or aortic valve regurgitation.

• Annual echocardiography to examine the ascending aorta in situations with modest aortic dimensions and a sluggish aortic dilatation rate. Echocardiography is necessary with increasing frequency when the aortic root diameter is over 4.5 cm in adults if aortic dilatation is greater than 0.5 cm per year, and if substantial aortic regurgitation exists.

• Beta-blocking therapy to alleviate hemodynamic stress on the aortic wall.

What Are the Key Challenges in Cardiovascular Management?

• If the aorta is dilated, beta-blocker therapy should be considered at any age; however, preventative treatment may be more successful in patients with aortic diameters less than four cm.

• Aorta dissection risk factors include an aorta diameter of more than five cm, aortic dilatation that extends beyond the sinus of Valsalva, a rapid rate of dilatation (45% per year, or 1.5 mm per year in adults), and a family history of aortic dissection.

• Annual cardiovascular evaluations, including a clinical history, examination, and echocardiography, should be provided.

• Serial echocardiography is advised in children at six to twelve-month intervals, with the frequency determined by aorta diameter (relative to body surface area) and rate of aortic dilatation.

• When the aorta diameter at the sinus of Valsalva exceeds five centimeters, prophylactic aortic root surgery is recommended.

Other therapeutic interventions include the following:

Anticoagulant drugs, such as Warfarin, are required following prosthetic heart valve installation.

• Intravenous antibiotic therapy is essential for cardiac and noncardiac surgeries to prevent bacterial endocarditis.

• If hormonal treatment begins before puberty, progesterone and estrogen medication can be utilized to induce puberty and reduce the patient's overall height. There is currently no conclusive data available to prove if this therapy reduces the severity of scoliosis.

• Conservative treatment of protrusion acetabuli consists primarily of physiotherapy by forced stretching (femoral neck stress fractures might occur), weight extension on an abduction frame, local heating, and reeducation regarding everyday activities.

• Myopia can be treated with refraction correction.

• Patients with flat feet can wear shoes that provide appropriate arch support, although specialized orthotics may be required. Guidelines for diagnosing and treating pediatric flatfoot have been developed.

• Psychological treatment can help families deal with feelings of denial, anger, blame, melancholy, or guilt.

Future therapy strategies are as follows.

• It is important to stress that an angiotensin-II receptor blocker (ARB) regimen is currently advised as a first-line treatment. Some cardiologists specializing in MFS continue to treat their patients with beta-blockers to cover both arms of the route. However, no studies have been published that formally suggest this strategy.

• The current gold standard for treating aortic aneurysms in MFS is prophylactically using beta blockers. However, beta blockers do not prevent later-life surgery.

• Marfan mice were treated with TGFβ-neutralizing antibody via intraperitoneal injection.

• In preliminary observational research, 17 juvenile MFS patients with progressive aortic enlargement, despite adequate medical care, were administered an angiotensin receptor blocker and monitored for 12 to 42 months. Patients' aortic root dimensions changed at a significantly slower rate. This trial offered the first evidence of a significant benefit of using angiotensin receptor blockers over conventional therapy to reduce aortic root dilatation in individuals with severe pediatric MFS.

The following are some genetic counseling points for patients and their families.

• If neither biological parent is affected, the patient's siblings have a low likelihood of recurrence; nonetheless, gonadal mosaicism has been linked to numerous affected offspring born to unaffected parents. The risk is 50 percent if one parent is affected.

• If the patient's spouse is normal, the probability of recurrence for his or her offspring is 50 percent. Homozygous MFS was discovered in the instance of an affected spouse. Compound heterozygosity at the FBN1 locus was confirmed molecularly; the infant was seriously affected and died young.

• The variety of MFS should be highlighted during counseling because an afflicted child may be more or less impacted than the affected parent.

Conclusion

It is critical to identify Marfan syndrome early. Despite the high mortality and morbidity associated with the condition of Marfan syndrome, early medicinal and surgical intervention can extend the lives of many patients. Continuing research holds the prospect of greater advancements. This case demonstrates the significance of gathering a comprehensive family history and the utility of clinical correlation when evaluating individuals with odd physical findings. Early detection of this condition by physicians will aid in initiating treatment and proper management, including educating patients and providing genetic counseling and an opportunity for relative screening.